Compare iShares Core S&P 500 ETF (IVV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Smith & Nephew plc — how do they compare? iShares Core S&P 500 ETF trades at $776.18, while Smith & Nephew plc trades at $29.85 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| IVV | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $776.81 | $38.70 |
52-Week Low | $634.93 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $776.77, up 0.01% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from strong institutional interest, as First Bank & Trust increased its stake by 24.8% in Q2 2026 (SEC filing, August 11, 2026), while Financial Advisory Corp reduced holdings by 3.1%. Market sentiment is mixed amid record highs and inflation concerns, with JPMorgan raising its S&P 500 target to 8,000 (FXEmpire, August 10, 2026).
Outlook remains positive due to robust corporate earnings and AI-driven growth, but risks include high valuations and potential pullbacks. Investors should focus on long-term diversification benefits, with the dividend offering steady income. Key resistance is at $777, with support at $772.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
